The genomic medicine space has seen incredible success, but investors are overlooking it. For once, it’s not efficacy that’s ...

Last night, news broke that President-Elect Donald Trump had nominated Robert F Kennedy Jr (aka RFK Jr) as US Health ...

Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...

Mendelsohn – using history as a guide – suggests there will be a layering of new laws, with, for example, a push for changes ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Pelacarsen is in a cardiovascular outcomes trial in patients with elevated Lp (a) levels, with results expected in 2025, ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

DXPs can now eliminate swivel chair processes. Commercial organisations can integrate existing systems with a DXP and have ...

23andMe is currently trading at around $3.15, down from more than $18 at the start of the year and more than $200 on its ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.